SELLAS Life Sciences (SLS) Other Non-Current Liabilities (2011 - 2022)

SELLAS Life Sciences (SLS) has 12 years of Other Non-Current Liabilities data on file, last reported at $170000.0 in Q3 2022.

• Other Non-Current Liabilities for Q3 2022 came in at $170000.0, down 96.62% year-over-year; the trailing twelve-month figure through Sep 2022 was $170000.0 (down 96.62% YoY), and the FY2021 annual result was $296000.0, down 93.61% from the prior year.
• Other Non-Current Liabilities fell to $170000.0 in Q3 2022 per SLS's latest filing, from $181000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.3 million in Q3 2018 and troughed at $170000.0 in Q3 2022.
• A 5-year average of $3.9 million and a median of $4.8 million in 2019 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2018 and 2022: Other Non-Current Liabilities soared 320.29% in 2018, then plunged 96.62% in 2022.
• A 5-year view of Other Non-Current Liabilities shows it stood at $4.3 million in 2018, then gained by 13.55% to $4.9 million in 2019, then declined by 5.68% to $4.6 million in 2020, then sank by 93.61% to $296000.0 in 2021, then sank by 42.57% to $170000.0 in 2022.
• Business Quant data shows SLS's Other Non-Current Liabilities at $170000.0 in Q3 2022, $181000.0 in Q2 2022, and $296000.0 in Q1 2022.